Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 127

1.

The immune cell landscape in kidneys of patients with lupus nephritis.

Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network.

Nat Immunol. 2019 Jul;20(7):902-914. doi: 10.1038/s41590-019-0398-x. Epub 2019 Jun 17.

PMID:
31209404
2.

Novel paradigms in systemic lupus erythematosus.

Dörner T, Furie R.

Lancet. 2019 Jun 8;393(10188):2344-2358. doi: 10.1016/S0140-6736(19)30546-X. Epub 2019 Jun 6. Review.

PMID:
31180031
3.

Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways.

Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabathou S, Izmirly P, Clancy R, Belmont HM, Koenigsberg M, Mokrzycki M, Rominieki H, Graham JA, Rocca JP, Bornkamp N, Jordan N, Schulte E, Wu M, Pullman J, Slowikowski K, Raychaudhuri S, Guthridge J, James J, Buyon J, Tuschl T, Putterman C; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium.

Nat Immunol. 2019 Jul;20(7):915-927. doi: 10.1038/s41590-019-0386-1. Epub 2019 May 20.

PMID:
31110316
4.

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.

BMJ Open. 2019 Mar 20;9(3):e025687. doi: 10.1136/bmjopen-2018-025687.

5.

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.

Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Petri M, Fettiplace J, Roth DA, Ji B, Heath A.

Arthritis Rheumatol. 2019 Jul;71(7):1125-1134. doi: 10.1002/art.40861. Epub 2019 Jun 5.

PMID:
30771238
6.

Baricitinib for systemic lupus erythematosus - Authors' reply.

Wallace DJ, Furie RA, Tanaka Y, de Bono S, Hoffman RW.

Lancet. 2019 Feb 2;393(10170):402-403. doi: 10.1016/S0140-6736(18)32749-1. No abstract available.

PMID:
30712893
7.

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.

Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, Wang W, Christmann R, Gardet A, Pellerin A, Hamann S, Auluck P, Barbey C, Gulati P, Rabah D, Franchimont N.

J Clin Invest. 2019 Mar 1;129(3):1359-1371. doi: 10.1172/JCI124466. Epub 2019 Feb 18.

8.

Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.

Kello N, Khoury LE, Marder G, Furie R, Zapantis E, Horowitz DL.

Semin Arthritis Rheum. 2018 Dec 4. pii: S0049-0172(18)30493-1. doi: 10.1016/j.semarthrit.2018.11.005. [Epub ahead of print]

PMID:
30598332
9.

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.

van Vollenhoven RF, Stohl W, Furie RA, Fox NL, Groark JG, Bass D, Kurtinecz M, Pobiner BF, Eastman WJ, Gonzalez-Rivera T, Gordon D.

Lupus Sci Med. 2018 Nov 26;5(1):e000288. doi: 10.1136/lupus-2018-000288. eCollection 2018.

10.

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.

Merrill JT, Furie R, Werth VP, Khamashta M, Drappa J, Wang L, Illei G, Tummala R.

Lupus Sci Med. 2018 Nov 26;5(1):e000284. doi: 10.1136/lupus-2018-000284. eCollection 2018.

11.

Inflammatory arthritis: a unique presentation of human anaplasmosis.

El Khoury L, Furie R.

Clin Rheumatol. 2019 Jan;38(1):257-259. doi: 10.1007/s10067-018-4395-5. Epub 2018 Dec 11. Review.

PMID:
30539351
12.

Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients.

Huang W, Quach TD, Dascalu C, Liu Z, Leung T, Byrne-Steele M, Pan W, Yang Q, Han J, Lesser M, Rothstein TL, Furie R, Mackay M, Aranow C, Davidson A.

JCI Insight. 2018 Sep 6;3(17). pii: 122525. doi: 10.1172/jci.insight.122525. eCollection 2018 Sep 6.

13.

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW.

Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Erratum in: Lancet. 2018 Aug 11;392(10146):476.

PMID:
30043749
14.

Methods for high-dimensonal analysis of cells dissociated from cyropreserved synovial tissue.

Donlin LT, Rao DA, Wei K, Slowikowski K, McGeachy MJ, Turner JD, Meednu N, Mizoguchi F, Gutierrez-Arcelus M, Lieb DJ, Keegan J, Muskat K, Hillman J, Rozo C, Ricker E, Eisenhaure TM, Li S, Browne EP, Chicoine A, Sutherby D, Noma A; Accelerating Medicines Partnership RA/SLE Network, Nusbaum C, Kelly S, Pernis AB, Ivashkiv LB, Goodman SM, Robinson WH, Utz PJ, Lederer JA, Gravallese EM, Boyce BF, Hacohen N, Pitzalis C, Gregersen PK, Firestein GS, Raychaudhuri S, Moreland LW, Holers VM, Bykerk VP, Filer A, Boyle DL, Brenner MB, Anolik JH.

Arthritis Res Ther. 2018 Jul 11;20(1):139. doi: 10.1186/s13075-018-1631-y.

15.

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

Merrill JT, Petri MA, Buyon J, Ramsey-Goldman R, Kalunian K, Putterman C, Conklin J, Furie RA, Dervieux T.

Lupus Sci Med. 2018 May 23;5(1):e000263. doi: 10.1136/lupus-2018-000263. eCollection 2018.

16.

Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).

Kolstad KD, Li S, Steen V, Chung L; PHAROS Investigators.

Chest. 2018 Oct;154(4):862-871. doi: 10.1016/j.chest.2018.05.002. Epub 2018 May 16.

PMID:
29777655
17.

Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.

Hu Y, Carman JA, Holloway D, Kansal S, Fan L, Goldstine C, Lee D, Somerville JE, Latek R, Townsend R, Johnsen A, Connolly S, Bandyopadhyay S, Shadick N, Weinblatt ME, Furie R, Nadler SG.

Arthritis Rheumatol. 2018 Aug;70(8):1331-1342. doi: 10.1002/art.40476. Epub 2018 Jul 12.

18.

Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE.

Furie R, Wang L, Illei G, Drappa J.

Lupus. 2018 May;27(6):955-962. doi: 10.1177/0961203318758506. Epub 2018 Feb 20.

PMID:
29460699
19.

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting.

Berkowitz JC, Stein-Fishbein J, Khan S, Furie R, Sultan KS.

World J Gastrointest Pharmacol Ther. 2018 Feb 6;9(1):8-13. doi: 10.4292/wjgpt.v9.i1.8.

20.

Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.

Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.

Arthritis Rheumatol. 2018 Jun;70(6):868-877. doi: 10.1002/art.40439. Epub 2018 Apr 25.

Supplemental Content

Loading ...
Support Center